HC Wainwright Issues Optimistic Outlook for LifeMD Earnings

LifeMD, Inc. (NASDAQ:LFMD) – Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of LifeMD in a research report issued to clients and investors on Wednesday, March 11th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.04) per share for the quarter, up from their prior forecast of ($0.31). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD’s Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.33 EPS.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). The company had revenue of $46.87 million for the quarter, compared to the consensus estimate of $48.57 million. LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%.

LFMD has been the subject of several other research reports. Mizuho lowered their price target on LifeMD from $8.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, November 19th. BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research report on Tuesday. Lake Street Capital reduced their price objective on shares of LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. B. Riley Financial decreased their target price on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Finally, Zacks Research upgraded shares of LifeMD from a “strong sell” rating to a “hold” rating in a research note on Friday, December 19th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.86.

LifeMD Trading Down 3.2%

LifeMD stock opened at $3.93 on Friday. LifeMD has a 12 month low of $2.56 and a 12 month high of $15.84. The company has a market capitalization of $189.19 million, a price-to-earnings ratio of 15.12 and a beta of 1.92. The business’s fifty day simple moving average is $3.32 and its two-hundred day simple moving average is $4.56.

Institutional Investors Weigh In On LifeMD

Large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new position in LifeMD in the 4th quarter worth about $36,000. Magnus Financial Group LLC purchased a new stake in shares of LifeMD during the 4th quarter valued at about $41,000. Jain Global LLC purchased a new stake in shares of LifeMD during the 4th quarter valued at about $45,000. Quarry LP bought a new stake in shares of LifeMD in the third quarter worth approximately $52,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.